Navigation Links
Live Press Briefing on Findings of Biomedical Industry CEO Survey

SAN FRANCISCO, Jan. 9, 2012 EVENT:Live Press Briefing on Findings of Biomedical Industry CEO SurveyWHEN:Tuesday, Jan. 10, 2012 TIME:10 a.m. – 10:45 a.m. PT presentation and Q&A 

 WHO:-- CEOs from three biotechnology companies: NuVasive (NASDAQ: NUVA), Omniox and Theravance (NASDAQ: THRX) 

-- Executives from BayBio, California Healthcare Institute and PwC USWHERE:Grand Hyatt San Francisco 

Conference Theatre 

345 Stockton St. 

San Francisco, CA 94108  

To listen by phone in the United States: (800) 230-1951 (Logo: )

Findings of a new survey of biomedical company CEOs about the future of the biomedical industry will be unveiled at a live press briefing hosted by the California Healthcare Institute, BayBio and PwC in San Francisco on Tuesday, Jan. 10. Some of the questions that will be addressed during the briefing include:

  • What are the biggest threats to future growth of the biomedical industry?
  • How are biomedical companies adapting to new threats and opportunities?
  • Where are biomedical companies turning for capital, and who will finance new innovation in the future?
  • How does the relationship between industry and FDA help or hinder innovation?
  • What are the key state and federal policy issues that will influence the ability for the United States and California to maintain global leadership in biomedical innovation?
  • While the biomedical industry may be poised for explosive growth over the next five to 10 years, the pace will be determined by a confluence of factors — the political, economic and regulatory environment, the availability of capital, health reform, globalization and state and federal budget deficits. These factors and the relative risks and opportunities they represent to the biomedical industry are among the topics explored by the survey.

    The briefing will include a presentation of research highlights, followed by a candid discussion among the CEOs of three California-based biomedical companies. The briefing will allow time at the conclusion for questions from the audience and members of the media.

  • NuVasive, Alexis Lukianov, Chairman and CEO
  • Omniox, Stephen Cary, Ph.D., CEO and Co-Founder
  • Theravance, Rick Winningham, Chairman and CEO
  • BayBio, Gail Maderis, President and CEO
  • California Healthcare Institute, David Gollaher, Ph.D., President and CEO
  • PwC, Tracy Lefteroff, National Life Sciences Partner
  • About the California Healthcare Institute
    CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI's mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI's website is Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

    About BayBio
    BayBio is Northern California's life science association, supporting the regional bioscience community through advocacy, enterprise support, and the enhancement of research collaboration. Its members include organizations engaged in, or supportive of, research, development and commercialization of life science technologies. Online at BayBio on Twitter at @baybio

    About the PwC Network
    PwC firms help organizations and individuals create the value they're looking for. We're a network of firms in 158 countries with close to 169,000 people who are committed to delivering quality in assurance, tax and advisory services. Tell us what matters to you and find out more by visiting us at
    © 2011 PricewaterhouseCoopers LLP, a Delaware limited liability partnership. All rights reserved. PwC refers to the US member firm, and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see for further details.




    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
    2. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
    3. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
    4. Compressus Drives Programmable Workflow And Unprecedented Flexibility With Introduction of MEDxConnect™ v4.0
    5. Nations Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey
    6. Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu
    7. Epitomics, Inc. Receives Notice of Allowance from the United States Patent and Trademark Office for a Novel Method for Identifying Differentially Expressed Proteins
    8. Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care
    9. Optics Express Focus Issue: Collective phenomena in photonic, plasmonic and hybrid structures
    10. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
    11. Nexcelom Bioscience to Distribute FCS Express 4 Cytometry Software with Cellometer Vision CBA Instruments
    Post Your Comments:
    (Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
    (Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
    (Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
    (Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
    Breaking Biology Technology:
    (Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
    (Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
    (Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: ) , ... but it also plays a fundamental part in enabling and ...
    Breaking Biology News(10 mins):